Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ADAP | Ordinary Shares with a nominal value of GBP0.001 per share | Purchase | $9.95K | +12.6K | $0.79 | 12.6K | Jun 1, 2021 | Held by Trust | F1, F2, F3 | |
holding | ADAP | Ordinary Shares with a nominal value of GBP0.001 per share | 60.2K | Jun 1, 2021 | Held by Trust | F4 | |||||
holding | ADAP | Ordinary Shares with a nominal value of GBP0.001 per share | 70.6K | Jun 1, 2021 | Direct | F5 |
Id | Content |
---|---|
F1 | The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. |
F2 | The 12,600 ordinary shares reported in Column 4 and Column 5 are represented by 2,100 ADSs. |
F3 | The price reported in Column 4 of $0.79 per ordinary share is derived from the weighted average purchase price paid on June 1, 2021 of $4.745 per ADS divided by six. |
F4 | The 60,180 ordinary shares reported in Column 5 are represented by 10,030 ADSs. These shares are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. |
F5 | The 70,584 ordinary shares reported in Column 5 are represented by 11,764 ADSs. These shares are held in the form of ADSs by Mr. Alleva. |